Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes
NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Competitor Analysis: Targeted Therapy of Diabetes
http://www.reportlinker.com/p0483024/Competitor-Analysis-Targeted-Therapy-of-Diabetes.html
Product description
The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:
-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.
Insulin
Rec Human Insulin for Injection (2nd Generation)
Biosimilar Rec Human Insulin for Injection (2nd Generation) in
Regulated Markets
Rhu Insulin (2nd Generation) in Off-Patent Countries: China
Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia
Rhu Insulin (2nd Generation) in Off-Patent Countries: India
Rhu Insulin (2nd Generation) in Off-Patent Countries: Others
Modern Insulin Analogs (3rd Generation) for Injection
Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets
Tailored and Novel Insulin Analogs (4th Generation) for
Injection
Human Insulin with Drug Delivery for Injection
Other Long-Acting Insulin for Injection
Transgenic Human Insulin for Injection
Insulin/GLP-1 Combination Products
Inhaled Insulin
Oral Insulin
Transdermal Insulin
Others
PPAR Agonists
PPAR alpha A < p>
PPAR gamma Agonists / Insulin Sensitizer
PPAR alpha and gamma Agonists
PPAR delta Agonists
PPAR delta and gamma Agonists
PPAR alpha and delta Agonists
PPAR pan Agonists (alpha, gamma and delta)
Unspecified PPAR Agonists
Dipeptidyl peptidase-IV (DPP-IV) Inhibitors
GLP-1 Receptor Agonists
GLP-1 Analogs with Daily SC Injections
GLP-1 Analogs with Once Weekly SC Injections
GLP-1 Analogs with Bi-Weekly or Monthly SC Injections
Other GLP-1 Analogs for SC Injections
GLP-1 Analogs in Drug Delivery Formulations/Devices for
Parenteral Administration
GLP-1 Analogs in Drug Delivery Formulations for Oral
Administration
Oral Small Molecule GLP-1 Receptor Agonists
Dual Target GLP-1 Receptor Agonists / Combination Products
GLP-1 Analogs in Other, Non-Diabetes Indications
Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors
11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
Glucokinase Activators (GKA)
Other Emerging Diabetes Drugs
Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
Sirtuin (SIRT) Activators
Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
Glucagon Receptor (GCGR) Antagonists
Glucocorticoid Receptor (GCGR) Antagonists
Novel Insulin Sensitizers
G-Protein Coupled Receptor 119 (GPR119) Agonists
Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists
Other Glucometabolic Approaches
Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
Other Metabolic Approaches
FGF-21-Receptor Agonists
Anti-Inflammatory Approaches
Induction of Immune Tolerance
Pancreatic Beta Cell Protection & Regeneration
Pancreatic Islet Cell Transplantation
Various Antidiabetic Approaches
To order this report:
: Competitor Analysis: Targeted Therapy of Diabetes
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article